Pfizer to Close Australian Neulasta Biosimilar Plant, Production Moved to Croatia


According to a report on BioPharm, pharmaceutical company, Pfizer is set to close-down the Australian plant which produces the API for HSP-130, a candidate version of Amgen’s Neulasta. Pfizer will according to the report move production to Croatia.

Pfizer according to the report will wind up operations at the facility in the Adelaide suburb Thebarton by 2021, citing existing capacity and a desire to consolidate manufacturing activities.

Currently, there are about 89 people employed at the plant but the company is expected to redeploy the staff.

The closure comes as a bit of a surprise given the fact that Pfizer had in March of 2016 announced its intention to expend about $21m in order to expand the plant in Australia for the manufacture the HSP-130.

Source: BioPharm

Print Friendly, PDF & Email
About Bob Aroture 556 Articles
Bob is a Senior Editor and Content Development Manager at Nigerian Law Intellectual Property Watch. He holds a BS degree, with a major in biochemistry. He works directly with the Newsroom Team. His focus areas are technology and innovation, and pharmaceutical technology. Email: